Truist Financial lifted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th.

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other large-cap value stocks. The market outlook is as uncertain as it gets. On January 18 ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks on Jim Cramer’s radar. Jim Cramer, host of Mad Money, recently emphasized ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

Eli Lilly's third quarter performance shows us the strength across key metrics, with especially impressive momentum in its core growth drivers. The company delivered total revenue of $11.44 ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...

Begin your TipRanks Premium journey today. Eli Lilly & Co (LLY) Company Description: Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical ...